Sydney:12/24 22:26:56

Tokyo:12/24 22:26:56

Hong Kong:12/24 22:26:56

Singapore:12/24 22:26:56

Dubai:12/24 22:26:56

London:12/24 22:26:56

New York:12/24 22:26:56

Live Updates  >  Live Update Details

2026-10-23 14:20:21

[Heineken Warns: Pubs and Restaurants Must Adapt to Weight-Loss Drug Craze or Face Customer Loss] (1) A presentation from Heineken shows that the company has urged pubs and restaurants in the UK to adapt to the weight-loss drug craze or risk losing customers and revenue. (2) This is a rare admission from a major alcohol producer that GLP-1 drugs pose a threat to beer sales. JPMorgan research shows that about 10 million people in the US used Novo Nordisk's semaglutide drugs Ozempic and Wegovy last year. (3) The widespread use of these drugs is having a ripple effect on the consumer goods industry, including reducing consumer cravings for sweets and snacks, increasing demand for clothing alterations, and prompting companies to rush to launch products that can alleviate the side effects of the drugs. (4) Heineken is the world's second-largest beer manufacturer, after Anheuser-Busch InBev. Heineken told its catering and pub industry clients that GLP-1 drugs may reduce the willingness to drink and put pressure on beer and cider sales by making consumers feel full more easily and reducing their consumption. (5) The company also warned that the traditional consumption scenario of drinking multiple pints of beer at a time may become increasingly difficult to maintain.

Real-Time Popular Commodities

Instrument Current Price Change

XAU

3610.26

-14.75

(-0.41%)

XAG

42.657

-0.190

(-0.44%)

CONC

82.79

0.35

(0.42%)

OILC

92.65

1.27

(1.38%)

USD

103.930

-0.010

(-0.01%)

EURUSD

1.0970

0.0003

(0.03%)

GBPUSD

1.3087

-0.0001

(-0.00%)

USDCNH

6.6881

-0.0016

(-0.02%)

Hot News